Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Description: Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and lingering questions left unanswered by the pivotal ARASENS study.